Holen Sie sich die Stockscreener-App
35.50
2.47%
-0.90
Handel nachbörslich:
35.50
Schlusskurs vom Vortag:
$36.40
Offen:
$36.37
24-Stunden-Volumen:
479.82K
Relative Volume:
0.44
Marktkapitalisierung:
$3.42B
Einnahmen:
$225.27M
Nettoeinkommen (Verlust:
$-140.06M
KGV:
-22.22
EPS:
-1.5974
Netto-Cashflow:
$-87.93M
1W Leistung:
+0.28%
1M Leistung:
-4.75%
6M Leistung:
+10.28%
1J Leistung:
+45.79%
1-Tages-Spanne:
$35.29
$36.63
1-Wochen-Bereich:
$35.17
$37.06
52-Wochen-Spanne:
$22.09
$40.58
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
35.50 | 3.54B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-09-04 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA initiates expansion phase for cancer drug IDE892 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR Newswire
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEAYA Biosciences Inc (IDYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEAYA Biosciences Inc (IDYA) Balance Sheet - TradingKey
IDYA|IDEAYA Biosciences Inc|Price:35.400|Chg%:-0.830 - TradingKey
IDYA|IDEAYA Biosciences Inc|Price:36.030|Chg%:-0.200 - TradingKey
ETFs Investing in IDEAYA Biosciences, Inc. Stocks - TradingView
IDEAYA Biosciences (IDYA) Stock Analysis: Exploring A 47.49% Upside Potential - DirectorsTalk Interviews
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing - Stock Traders Daily
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - BioSpace
IDEAYA Biosciences to present new clinical tria... - Pluang
Ideaya Biosciences chief accounting officer sells $382,130 in stock - Investing.com
Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com - Investing.com Nigeria
Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com - Investing.com Nigeria
Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing - Moomoo
IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan
Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer - Ad-hoc-news.de
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - AOL.com
Form 144 IDEAYA Biosciences For: 7 July By Investing.com - Investing.com South Africa
[144] IDEAYA Biosciences, Inc. SEC Filing - Stock Titan
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63 - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
IDYA Maintains Outperform Rating by RBC Capital -- Price Target Lowered to $48 - GuruFocus
RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating - Moomoo
Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com - Investing.com South Africa
Ideaya Biosciences stock hits 52-week high at $39.28 - Investing.com
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBITDA forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ideaya Biosciences Inc-Aktie (IDYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Sale |
40.01 |
9,550 |
382,131 |
26,466 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):